Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 8/20 | 0.66 |
| ▸ | USP47 | Q96K76 | 2/20 | 0.66 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | PDE7A | Q13946 | 9/20 | 0.48 |
| ▸ | PDE7B | Q9NP56 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2680133 | 0.82 | USP7 (0.63) | USP7USP47IDO1PDE7APDE7B | |
| SCHEMBL3722833 | 0.81 | USP7 (0.76) | USP7USP47IDO1PDE7APDE7B | |
| SCHEMBL2681294 | 0.81 | USP7 (0.79) | USP7USP47IDO1PDE7APDE7B | |
| SCHEMBL3717157 | 0.81 | USP7 (0.69) | USP7USP47IDO1PDE7APDE7B | |
| SCHEMBL2680694 | 0.81 | USP7 (0.80) | USP7USP47IDO1PDE7APDE7B | |
| SCHEMBL2680101 | 0.80 | USP7 (0.64) | USP7USP47IDO1PDE7APDE7B | |
| SCHEMBL2680726 | 0.80 | USP7 (1.00) | USP7USP47IDO1TSHRMAPK1 | |
| SCHEMBL2679939 | 0.79 | USP7 (0.79) | USP7USP47IDO1PDE7APDE7B | |
| SCHEMBL3717082 | 0.79 | USP7 (0.76) | USP7USP47IDO1PDE7APDE7B | |
| SCHEMBL3716355 | 0.79 | USP7 (0.79) | USP7USP47IDO1PDE7APDE7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120114765-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | PROGENRA | 2012-05-10 | — | — | US | claimed |
| WO-2010114881-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | PROGENRA INC. (US) | 2010-10-07 | — | — | WO | claimed |
| US-8680139-B2 | Anti-neoplastic compounds, compositions and methods | PROGENRA (US) | 2014-03-25 | — | — | US | disclosed |
| US-20120114765-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | PROGENRA | 2012-05-10 | — | — | US | disclosed |
| WO-2010114881-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | PROGENRA INC. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114765-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | SERPINB1, TP53, CTSE | USP7 437/4885USP47 315/4885IDO1 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.